PURPOSE: Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS: We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P < .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02). CONCLUSION: Use of BRAF inhibition results in robust and durable responses in BRAF V600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.
PURPOSE:Children with pediatric gliomas harboring a BRAFV600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS: We collected clinical, imaging, molecular, and outcome information from patients with BRAFV600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS: Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P < .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02). CONCLUSION: Use of BRAF inhibition results in robust and durable responses in BRAFV600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Matthew Mistry; Nataliya Zhukova; Daniele Merico; Patricia Rakopoulos; Rahul Krishnatry; Mary Shago; James Stavropoulos; Noa Alon; Jason D Pole; Peter N Ray; Vilma Navickiene; Joshua Mangerel; Marc Remke; Pawel Buczkowicz; Vijay Ramaswamy; Ana Guerreiro Stucklin; Martin Li; Edwin J Young; Cindy Zhang; Pedro Castelo-Branco; Doua Bakry; Suzanne Laughlin; Adam Shlien; Jennifer Chan; Keith L Ligon; James T Rutka; Peter B Dirks; Michael D Taylor; Mark Greenberg; David Malkin; Annie Huang; Eric Bouffet; Cynthia E Hawkins; Uri Tabori Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Maura Massimino; Filippo Spreafico; Graziella Cefalo; Riccardo Riccardi; John David Tesoro-Tess; Lorenza Gandola; Daria Riva; Antonio Ruggiero; Laura Valentini; Elena Mazza; Lorenzo Genitori; Concezio Di Rocco; Piera Navarria; Michela Casanova; Andrea Ferrari; Roberto Luksch; Monica Terenziani; Maria Rosa Balestrini; Cesare Colosimo; Franca Fossati-Bellani Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister Journal: Nat Genet Date: 2013-06-30 Impact factor: 38.330
Authors: Thomas E Merchant; Larry E Kun; Shengjie Wu; Xiaoping Xiong; Robert A Sanford; Frederick A Boop Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Hezhe Lu; Shujing Liu; Gao Zhang; Yueyao Zhu; Dennie T Frederick; Yi Hu; Wenqun Zhong; Sergio Randell; Norah Sadek; Wei Zhang; Gang Chen; Chaoran Cheng; Jingwen Zeng; Lawrence W Wu; Jie Zhang; Xiaoming Liu; Wei Xu; Clemens Krepler; Katrin Sproesser; Min Xiao; Benchun Miao; Jianglan Liu; Claire D Song; Jephrey Y Liu; Giorgos C Karakousis; Lynn M Schuchter; Yiling Lu; Gordon Mills; Yusheng Cong; Jonathan Chernoff; Jun Guo; Genevieve M Boland; Ryan J Sullivan; Zhi Wei; Jeffrey Field; Ravi K Amaravadi; Keith T Flaherty; Meenhard Herlyn; Xiaowei Xu; Wei Guo Journal: Nature Date: 2017-09-27 Impact factor: 49.962
Authors: David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Jinghui Zhang; Gang Wu; Claudia P Miller; Ruth G Tatevossian; James D Dalton; Bo Tang; Wilda Orisme; Chandanamali Punchihewa; Matthew Parker; Ibrahim Qaddoumi; Fredrick A Boop; Charles Lu; Cyriac Kandoth; Li Ding; Ryan Lee; Robert Huether; Xiang Chen; Erin Hedlund; Panduka Nagahawatte; Michael Rusch; Kristy Boggs; Jinjun Cheng; Jared Becksfort; Jing Ma; Guangchun Song; Yongjin Li; Lei Wei; Jianmin Wang; Sheila Shurtleff; John Easton; David Zhao; Robert S Fulton; Lucinda L Fulton; David J Dooling; Bhavin Vadodaria; Heather L Mulder; Chunlao Tang; Kerri Ochoa; Charles G Mullighan; Amar Gajjar; Richard Kriwacki; Denise Sheer; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; Suzanne J Baker; David W Ellison Journal: Nat Genet Date: 2013-04-14 Impact factor: 38.330
Authors: Theodore Nicolaides; Jean M Mulcahy Levy; Karisa C Schreck; Andrew Morin; Guisheng Zhao; Amy N Allen; Patrick Flannery; Michael Glantz; Adam L Green; Chris Jones; Kenneth L Jones; Lindsay B Kilburn; Kellie J Nazemi; David Samuel; Bridget Sanford; David A Solomon; Jiawan Wang; Christine A Pratilas Journal: Clin Cancer Res Date: 2021-08-25 Impact factor: 12.531
Authors: A Trasolini; C Erker; S Cheng; C Crowell; K McFadden; R Moineddin; M A Sargent; D Mata-Mbemba Journal: AJNR Am J Neuroradiol Date: 2022-07-21 Impact factor: 4.966
Authors: Alyssa J Penning; Alyaa Al-Ibraheemi; Michael Michal; Brandon T Larsen; Soo-Jin Cho; Christina M Lockwood; Vera A Paulson; Yajuan J Liu; Lukáš Plank; Karen Fritchie; Carol Beadling; Tanaya L Neff; Christopher L Corless; Erin R Rudzinski; Jessica L Davis Journal: Mod Pathol Date: 2021-04-13 Impact factor: 8.209
Authors: Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029
Authors: Karen D Wright; Xiaopan Yao; Wendy B London; Pei-Chi Kao; Lia Gore; Stephen Hunger; Russ Geyer; Kenneth J Cohen; Jeffrey C Allen; Howard M Katzenstein; Amy Smith; Jessica Boklan; Kellie Nazemi; Tanya Trippett; Matthias Karajannis; Cynthia Herzog; Joseph Destefano; Jennifer Direnzo; Jay Pietrantonio; Lianne Greenspan; Danielle Cassidy; Debra Schissel; John Perentesis; Mitali Basu; Tomoyuki Mizuno; Alexander A Vinks; Sanjay P Prabhu; Susan N Chi; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2020-11-02 Impact factor: 3.838